THOC6

Across TCGA pan-cancer cohorts, THOC6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated THOC6 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher THOC6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated THOC6 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where THOC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.407	0.772	.005	26	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.361	<.001	18	view →
HNSC	DFS	Median	All	0.698	1.000	.020	13	view →
LUAD	OS	Tertile	III,IV	1.000	0.339	.006	9	view →
PDAC	OS	Tertile	II,III,IV	0.698	0.937	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

THOC6–CCRCC (DFS)

Open the CCRCC breakdown →